Regeneron Receives Another CRL for Eylea 8 mg
Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.
The US Food and Drug Administration (FDA) issued a complete response letter (CRL) for Regeneron's prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg, citing unresolved issues at Novo Nordisk's Bloomington, Indiana, plant.
- In August 2025, the FDA rejected a new blood cancer therapy due to problems at the same Novo Nordisk-owned site.
- Quality control lapses were found in November 2024, including a "pest" on the manufacturing line.
- The FDA tagged Novo's Indiana facility with an official action indicated (OAI) label.
No official statement from Regeneron regarding the CRL was provided.
Author's summary: Regeneron faces FDA setbacks due to manufacturing issues.
More News
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- Another Coup In Africa, Soldiers Appear On State TV To Announce Takeover
- Benin authorities say coup attempt foiled, President Talon safe
- Vilnius Airport grounds flights after suspected Belarusian balloons detected
- Benin: the government declares coup attempt has been 'foiled'
- Tunbridge Wells gridlocked as residents queue for fresh water after five-day outage
- Women’s Big Bash League 2025-26 results
- Après la tentative de coup d'Etat au Bénin, la menace du pouvoir kaki plus présente que jamais en Afrique
- PREDICTED TEAM: How Scorchers will line up for BBL opener
- Canada's Air Transat to suspend flights